Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update - Roskoski, Robert (Pharmacological research, 2020)
Keywords: Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - classification; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Catalytic spine; Drug Approval; Humans; Hydrophobic interaction; Protein kinase inhibitor classification; Protein Kinase Inhibitors - chemistry; Protein Kinase Inhibitors - classification; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein kinase structure; Regulatory spine; Shell residues; United States; United States Food and Drug Administration; United States; CS1; GRL; ALL; Sorafenib (PubMED CID: 216239); F; Hydrophobic interaction; Regulatory spine; CDK; C-spine; BP; EGFR; Pexidartinib (PubMED CID: 25151352); RS1; Protein kinase structure; PI3K; Erdafitinib (PubMED CID: 67462786); Shell residues; LipE; PDGFR; VEGFR; Fedratinib (PubMED CID: 16722836); FKBP12/mTOR; Sh2; Trametinib (PubMED CID: 11707110); CML; GK; NSCLC; Crizotinib (PubMED CID: 9033117); PKA; Entrectinib (PubMED CID: 25141092); CL; Dabrafenib (PubMED CID: 44462760); FGFR; AS; KLIFS-3; Binimetinib (PubMED CID: 10288191); Imatinib (PubMED CID: 123596); Catalytic spine; LE; Ro5; R-spine; Protein kinase inhibitor classification